BRK-B vs NHS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
NHS presents a classic 'yield trap' scenario, characterized by a stable Piotroski F-Score of 5/9 but a critically unsustainable dividend payout ratio of 164.55%. While the stock is significantly undervalued relative to its Graham Number ($10.51) and Intrinsic Value ($10.26), the market is pricing in the risk of a dividend cut and a completely bearish technical trend (0/100). The fund maintains a stable financial health profile with low debt/equity, but the disconnect between earnings and distributions is a primary concern.
Compare Another Pair
Related Comparisons
BRK-B vs NHS: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Neuberger Berman Income Funds - Neuberger High Yield Strategies Fund Inc. (NHS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.